Cefiderocol : A Novel Siderophore Cephalosporin against Multidrug‐Resistant Gram‐Negative Pathogens
Cefiderocol (CFDC), (formerly S‐649266), is a novel injectable siderophore cephalosporin developed by Shionogi & Co., Ltd., with potent in vitro activity against Gram‐negative pathogens including multidrug‐resistant (MDR) Enterobacteriaceae and non‐fermenting organisms, such as Pseudomonas aeruginosa, Acinetobacter baumannii, Burkholderia cepacia, and Stenotrophomonas maltophilia. Characterized by its siderophore catechol‐moiety, CFDC uses a “trojan‐horse approach” to navigate through the bacterial periplasmic space, thus evading various beta‐lactam degrading enzymes and other mechanisms of resistance present in Gram‐negative bacteria. More specifically in carbapenem‐resistant Enterobacteriaceae, CFDC has been shown to have activity against extended spectrum beta‐lactamases (ESBLs), such as CTX‐type, SHV‐type, and TEM‐type, as well as the Ambler classes of beta‐lactamases, including class A (KPC), class B (NDM, IMP, and VIM), class C (AmpC), and class D (OXA, OXA‐24, OXA‐48, and OXA‐48‐like). In addition to the strong activity that CFDC has been shown to have against MDR P. aeruginosa, it has also displayed activity against the OXA‐23, OXA‐24, and OXA‐51, beta‐lactamases commonly found in MDR A. baumannii. Cefiderocol was recently approved by the US Food and Drug Administration (FDA) for use in complicated urinary tract infections (cUTI), including pyelonephritis, for use in patients 18 years or older with limited or no alternative options for treatment, and is currently being evaluated in a phase III trial for use in nosocomial pneumonia caused by Gram‐negative pathogens. The unique features and enhanced activity of CFDC suggest that it is likely to serve as a viable therapeutic option in the treatment of MDR Gram‐negative infections. The purpose of this review is to provide an overview of previously published literature explaining CFDC’s pharmacology, pharmacokinetic / pharmacodynamic (PK / PD) properties, microbiologic activity, resistance mechanisms, safety parameters, dosing and administration, clinical data, and potential place in therapy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - 40(2020), 12, Seite 1228-1247 |
| Beteiligte Personen: |
Abdul‐Mutakabbir, Jacinda C. [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2020 Pharmacotherapy Publications, Inc. |
|---|
| Umfang: |
20 |
|---|
| doi: |
10.1002/phar.2476 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY012272949 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY012272949 | ||
| 003 | DE-627 | ||
| 005 | 20230307235531.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230219s2020 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1002/phar.2476 |2 doi | |
| 028 | 5 | 2 | |a PHAR_PHAR2476.xml |
| 035 | |a (DE-627)WLY012272949 | ||
| 035 | |a (WILEY)PHAR2476 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.40 |2 bkl | ||
| 084 | |a 44.38 |2 bkl | ||
| 100 | 1 | |a Abdul‐Mutakabbir, Jacinda C. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cefiderocol |b A Novel Siderophore Cephalosporin against Multidrug‐Resistant Gram‐Negative Pathogens |
| 264 | 1 | |c 2020 | |
| 300 | |a 20 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2020 Pharmacotherapy Publications, Inc. | ||
| 520 | |a Cefiderocol (CFDC), (formerly S‐649266), is a novel injectable siderophore cephalosporin developed by Shionogi & Co., Ltd., with potent in vitro activity against Gram‐negative pathogens including multidrug‐resistant (MDR) Enterobacteriaceae and non‐fermenting organisms, such as Pseudomonas aeruginosa, Acinetobacter baumannii, Burkholderia cepacia, and Stenotrophomonas maltophilia. Characterized by its siderophore catechol‐moiety, CFDC uses a “trojan‐horse approach” to navigate through the bacterial periplasmic space, thus evading various beta‐lactam degrading enzymes and other mechanisms of resistance present in Gram‐negative bacteria. More specifically in carbapenem‐resistant Enterobacteriaceae, CFDC has been shown to have activity against extended spectrum beta‐lactamases (ESBLs), such as CTX‐type, SHV‐type, and TEM‐type, as well as the Ambler classes of beta‐lactamases, including class A (KPC), class B (NDM, IMP, and VIM), class C (AmpC), and class D (OXA, OXA‐24, OXA‐48, and OXA‐48‐like). In addition to the strong activity that CFDC has been shown to have against MDR P. aeruginosa, it has also displayed activity against the OXA‐23, OXA‐24, and OXA‐51, beta‐lactamases commonly found in MDR A. baumannii. Cefiderocol was recently approved by the US Food and Drug Administration (FDA) for use in complicated urinary tract infections (cUTI), including pyelonephritis, for use in patients 18 years or older with limited or no alternative options for treatment, and is currently being evaluated in a phase III trial for use in nosocomial pneumonia caused by Gram‐negative pathogens. The unique features and enhanced activity of CFDC suggest that it is likely to serve as a viable therapeutic option in the treatment of MDR Gram‐negative infections. The purpose of this review is to provide an overview of previously published literature explaining CFDC’s pharmacology, pharmacokinetic / pharmacodynamic (PK / PD) properties, microbiologic activity, resistance mechanisms, safety parameters, dosing and administration, clinical data, and potential place in therapy. | ||
| 700 | 1 | |a Alosaimy, Sara |4 aut | |
| 700 | 1 | |a Morrisette, Taylor |4 aut | |
| 700 | 1 | |a Kebriaei, Razieh |4 aut | |
| 700 | 1 | |a Rybak, Michael J. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy |g 40(2020), 12, Seite 1228-1247 |w (DE-627)WLY01227206X |x 18759114 |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2020 |g number:12 |g pages:1228-1247 |g extent:20 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-ASE | ||
| 936 | b | k | |a 44.40 |q ASE |
| 936 | b | k | |a 44.38 |q ASE |
| 951 | |a AR | ||
| 952 | |d 40 |j 2020 |e 12 |h 1228-1247 |g 20 | ||